Developer · ATAI · United States

Atai Beckley N.V. (AtaiBeckley)

Clinical-stage biopharmaceutical company developing rapid-acting, convenient mental health treatments, including psychedelic and related CNS therapies for treatment-resistant depression and other psychiatric conditions. Formed in November 2025 through the strategic combination of atai Life Sciences and Beckley Psytech; redomiciled to Delaware (USA) in December 2025.

ataibeckley.com ↗

1compound
1program
1indication
Phase 2lead asset

Phase distribution

  • Phase 21

Modality

  • Psychedelic 1

Mechanism focus

Pipeline (1)

Deals & partnerships

  • Nov 5, 2025Acquisitionatai Life Sciences and Beckley Psytech complete strategic combination to form AtaiBeckleyAll-share combination (announced June 2025; valued at ~$390M) in which atai Life Sciences acquired Beckley Psytech Limited, closing November 5, 2025 to create AtaiBeckley. Beckley shareholders received ~105 million new shares (~28-31% of the combined company); the deal was conditioned on positive Phase 2b BPL-003 topline data and included a concurrent ~$30M private placement (Ferring Ventures, Adage Capital). atai's internal pipeline, including VLS-01, carried into the combined company.VLS-01source ↗

Recent activity

Trials recruiting · 1 recruiting of 1 sponsored

  • Phase 2VLS-01n=14248 sites · United States, Australia, United Kingdom

    Phase 2 Trial of VLS-01 Buccal Film in Treatment Resistant Depression (ELUMINA)

    Treatment Resistant DepressionNCT06524830 ↗

Competitive landscape

Other companies developing against Atai Beckley N.V. (AtaiBeckley)'s targets or indications.

Leadership & advisors (18)